Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - treatment
40
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF
CDK19-SELECTIVE INHIBITORS, AND METHODS OF USE THEREOF Researchers at Stanford have developed compounds that act as potent anti-cancer drugs which selectively inhibit CDK19 over CD8 and promise a greater therapeutic index and reduced systemic toxicity. Breast cancer remains the leading cause of cancer-related death among women worldwide. Patient mortality...
Published: 7/6/2023
|
Inventor(s):
Vincent Alford
,
Mark Smith
,
Michael Clarke
,
Jitendra Gurjar
,
Angera Kuo
Keywords(s):
CDK19
,
CDK8
,
Compound
,
Selective Inhibition
,
Therapeutic
,
Treatment
,
Triple Negative Breast Cancer
Category(s):
Technology Classifications > Biology
Stable, High-Yield Production of DT390-EGF Fusion Protein for
Treatment
of EGF-Receptor-Positive Cancers
This invention relates to the stable and high-yield production of a high-potency toxin protein called DT390-EGF. This toxin was developed for the
treatment
of EGF-receptor-positive cancers, including bladder cancer. Initial methods for synthesizing DT390-EGF relied on the use of E. coli. However, the production in E. coli was difficult to prepare and...
Published: 7/25/2024
|
Inventor(s):
Jung-hee Woo
,
David Neville
,
Arthur Frankel
,
Andrew Thorburn
,
Michael Glode
,
Thomas Flaig
Keywords(s):
cancers
,
DT390-EGF
,
EGF
,
Fusion
,
POSITIVE
,
Protein
,
RECEPTOR
,
treatment
,
VCXXXX
,
WKXXXX
,
XEXXXX
Category(s):
TherapeuticArea > Oncology
,
Application > Therapeutics
Diagnosis and
Treatment
of Pediatric Acute Neurologic Syndrome with Antineuronal Antibodies
The invention is a panel of five tests of patient sera for immune responses that may attack the brain and lead to the characteristic symptoms of pediatric acute neurologic syndrome (PANS). PANS is a condition defined by a sudden onset of obsessive-compulsive symptoms, eating restrictions, and other cognitive and/or behavioral symptoms. Currently, the...
Published: 7/25/2024
|
Inventor(s):
Susan Swedo
,
Christine Kirvan
,
Madelein Cunningham
Keywords(s):
ACUTE
,
antibodies
,
Antineuronal
,
Diagnosis
,
Listed LPM Greene as of 4/15/2015
,
Neurologic
,
pediatric
,
Post LPM Assignment Set 20150420
,
Pre LPM working set 20150418
,
Syndrome
,
treatment
,
VEXXXX
,
VNXXXX
,
WBXXXX
,
WIXXXX
,
XAXXXX
,
XCXXXX
Category(s):
TherapeuticArea > Psychiatry/Mental Health
,
TherapeuticArea > Neurology
,
TherapeuticArea > Immunology
,
Application > Research Materials
,
Application > Diagnostics
,
ResearchProducts > Antibodies
Synthetic Genes for the
Treatment
of Propionic Acidemia (PA) Caused by Mutations in Propionyl-coA Carboxylase Alpha (PCCA)
Propionic acidemia (PA) is an autosomal recessive metabolic disorder caused by mutations in either PCCA or PCCB. The products of these genes form the alpha and beta subunits of the enzyme propionyl-Co A carboxylase (PCC), a critically important mitochondrial enzyme involved in the catabolism of branched chain amino acids. NHGRI scientist have developed...
Published: 7/25/2024
|
Inventor(s):
Randy Chandler
,
Charles Venditti
Keywords(s):
Acidemia
,
ALPHA
,
Carbox
,
CAUSED
,
GENES
,
Lase
,
Mutations
,
PA
,
Pcca
,
Propionic
,
PropionylcoA
,
Synthetic
,
treatment
,
VPXXXX
,
WIXXXX
,
XEXXXX
Category(s):
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
,
TherapeuticArea > Cardiology
,
TherapeuticArea > Oncology
,
TherapeuticArea > Ophthalmology
,
TherapeuticArea > Dental
,
TherapeuticArea > Endocrinology
,
Application > Research Materials
High Concentration Methylcobalamin (Me-Cbl) or Combination of Methyl- and Hydroxocobalamin (Me/OH-Cbl) for the
Treatment
of Cobalamin C Deficiency and Related Disorders
Cobalamin C deficiency (cblC), caused by mutations in MMACHC, is the most common inborn error of intracellular vitamin B12 metabolism. NHGRI scientist have generated a number of Mmachc knockout mouse models. The cblC mice present with early lethality, recapitulate the neurological phenotype seen in patients, and have enabled proof of concept testing...
Published: 7/25/2024
|
Inventor(s):
Jennifer Sloan
,
Eirini (Irini) Manoli
,
Charles Venditti
Keywords(s):
C
,
Cobalamin
,
Combination
,
Concentration
,
DEFICIENCY
,
DISORDERS
,
High
,
Hydroxocobalamin
,
Me/OH-Cbl
,
Me-Cbl
,
Methyl-
,
Methylcobalamin
,
RELATED
,
treatment
,
VPXXXX
,
WKXXXX
Category(s):
Application > Therapeutics
,
TherapeuticArea > Cardiology
,
TherapeuticArea > Infectious Disease
,
TherapeuticArea > Ophthalmology
,
TherapeuticArea > Oncology
,
TherapeuticArea > Endocrinology
,
TherapeuticArea > Dental
Inhibition of Thioredoxin Reductase 1 (Trxr1) by Pyridine Compounds for Cancer
Treatment
This technology includes the use of pyridines for anticancer
treatment
. A common feature of cancer cells is a high level of reactive oxygen species with a concomitant increase of two antioxidative systems to combat the toxicity: the glutathione and thioredoxin systems. Inhibiting either, or both, of these systems is a promising avenue to target cancer...
Published: 7/25/2024
|
Inventor(s):
Ajit Jadhav
,
Diane Luci
,
Thomas Dexheimer
,
Anton Simeonov
,
Nathan Coussens
,
David Maloney
Keywords(s):
CANCER
,
Novel
,
PYRIDINES
,
Their
,
treatment
,
VCXXXX
,
WIXXXX
,
WKXXXX
,
XEXXXX
Category(s):
Application > Research Materials
,
TherapeuticArea > Oncology
,
Application > Therapeutics
Development of a Therapy for the
Treatment
of Zellweger Spectrum Disorder
This technology includes a method for selecting a therapeutic effective amount of one of two compounds (including naltriben and naltrin) for the
treatment
of Zellweger Spectrum Disorder (ZSD), or any disease associated with peroxisome dysfunction. The compounds were identified using a cell-image based high-content screening (HCS) assay to identify small...
Published: 7/25/2024
|
Inventor(s):
Patricia Dranchak
,
James Inglese
Keywords(s):
DEVELOP
,
DISORDER
,
Spectrum
,
THERAPY
,
TOOLS
,
treatment
,
VEXXXX
,
WIXXXX
,
WKXXXX
,
Zellweger
Category(s):
TherapeuticArea > Neurology
,
Application > Therapeutics
,
Application > Research Materials
Repurposing CDK Inhibitors for the
Treatment
of Zika Virus Infection
This invention includes the discovery and use of a group of CDK inhibitors that were found during a drug repurposing screen designed to find compounds that inhibit Zika virus caused cell death. The identified CDK inhibitors have all previously been used in clinical trials for other diseases, potentially reducing the long time course needed for new drug...
Published: 7/25/2024
|
Inventor(s):
Ruili Huang
,
Miao Xu
,
Wenwei Huang
,
Hengli Tang
,
Emily Lee
,
Cheng YiChen
,
Yi Zhou
,
Hongjun Song
,
Guo-Li Ming
,
Zhexing Wen
,
Wei Zheng
Keywords(s):
CDK
,
Infection
,
Inhibitors
,
Repurposing
,
treatment
,
VEXXXX
,
virus
,
VLXXXX
,
WIXXXX
,
WKXXXX
,
Zika
Category(s):
TherapeuticArea > Neurology
,
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
The Use of Emetine for the
Treatment
of SARS-CoV-2 Infection
This technology includes the clinical use of the small compound emetine for the
treatment
of SARS-CoV-2. Previous work has shown that emetine has antiviral properties against some DNA and RNA viruses. It is thought that the mechanism may involve blocking protein synthesis. Work has shown that emetine has potential antiviral activity in multiple tissues...
Published: 7/25/2024
|
Inventor(s):
Mark Henderson
,
Juan Marugan
,
Andreas Dulcey Gracia
,
Xin Hu
,
Marc Ferrer-Alegre
,
Noel Southall
Keywords(s):
Emetine
,
Infection
,
SARS-CoV-2
,
treatment
,
VLXXXX
,
WIXXXX
,
WKXXXX
Category(s):
TherapeuticArea > Infectious Disease
,
Application > Therapeutics
,
Application > Research Materials
Repurposed Use of the Alkaloids Emetine and Cephaeline to Treat Zika Virus Infection
This technology includes the use of two related compounds, Emetine and Cephaeline, as a potent inhibitor of the Zika virus (ZIKV). Emetine and it's analog Cephaeline were identified in a high-throughput assay aimed at identifying anti-ZIKV compounds. Both Emetine and Cephaeline are potent inhibitors of ZIKV infection in cell culture, and Emeline is...
Published: 7/25/2024
|
Inventor(s):
Emily Lee
,
Wei Zheng
,
Miao Xu
,
Ruili Huang
,
Shu Yang
,
Wenwei Huang
,
Khalida Shamim
,
Hao Li
,
Hengli Tang
Keywords(s):
compounds
,
Emetine
,
Flavivirus
,
Infection
,
Prevention
,
treatment
,
VLXXXX
,
WIXXXX
,
WKXXXX
Category(s):
Application > Therapeutics
,
TherapeuticArea > Infectious Disease
,
Application > Research Materials
1
2
3
4